Register of 2024 public money · GF0701
Medical products, appliances and equipment
In short. Studies of a pilot paying hospital prescribing units part of the savings find it raised biosimilar use, with small savings; none measures the retail generic substitution rate.
2024
€43.7bn, of public money, line 14 of 155
Strength of evidence
Limited level 2 of 4, on 1 of its 1 goals: Efficiency and medically guided control of spending on medicines · on rules or parts of the line, which have no separate cost
Studies
6 causal studies tied; 3 findings on its goals
Summary
Version 1 · written 19 October 2026 · history
What it is and who gets it
Medicines, medical devices and appliances reimbursed by the health insurance, mostly those patients obtain from pharmacies and suppliers: drugs, glasses, hearing aids and other devices.
Goals and the evidence on each
- Efficiency and medically guided control of spending on medicines: Limited, 3 findings
What the studies find
Of the 3 findings on its goals: 3 in the goal's direction, 0 mixed, 0 with no significant effect, 0 against it.
- Paying prescribing hospital units 30% of the savings, rather than a smaller share to the hospital, raised biosimilar use by 6.0 points for insulin glargine and 10.8 points for etanercept, saving 0.5% and 0.1% of spending (Vincent Attia et al., 2024); another evaluation agrees (Marion Tano et al., 2023).
- After mucolytics were delisted in 2006, their prescription fell while antitussive prescriptions rose, saving 32.1 million euros in four years (Sylvain Pichetti et al., 2011); patients who stopped anti-dementia drugs after their 2018 delisting declined faster cognitively than those who continued (S. Lecerf et al., 2026).
What is missing
- No causal study measures the retail generic substitution rate or the rules behind it: pharmacists' substitution, the 2012 rule tying third-party payment to generics, reference pricing (search of 19 October 2026) (search notes).
- No causal study was found of the reform that removed out-of-pocket costs on some glasses and hearing aids in 2020-2021, of drug price regulation or of fixed co-payments on medicines (search of 19 October 2026).
Other official evidence, without a causal design
- A review without a causal design puts medical devices, in and out of hospital, at 14,000 million euros and names « la participation des usagers, la maîtrise des prix et tarifs, et le contrôle des volumes » as savings levers (IGF-IGAS, 2024).
How this summary was made
Literature searched on 19 October 2026: causal evaluations of the reimbursement of medicines and medical devices published since the search of 4 October 2026, and older ones the search notes lack: generic substitution rules, biosimilar incentives, delisting, price regulation, co-payments on medicines, the reform that made some glasses and hearing aids free, early access and the hospital add-on list. Searched: the PubMed API (24 queries), the OpenAlex API (29 queries, then refused for the day), the HAL API (17 queries), the Crossref API (12 queries), the Irdes site (its lists of Questions d'économie de la santé and working papers), the Insee site; HAL's file server answered with a bot check, and the Drees and Cour des comptes sites' searches returned no usable results. Strength of evidence rated by the rule on the Method page.
- Version 1, 19 October 2026, written · by writer: First version. Latest updates
Under the register's two definitions
Broad definition: a causal study in the line
evaluated
At least one causal study is tied to this line, on all of it or on one of its rules; the line then counts in full, so this is an upper bound.
Strict definition: a single measure with its own cost and study
not yet evaluated
A spending category: the register holds no separate cost for the measures inside it, so none of its money counts under this definition.
6 causal studies are tied to this line, the latest from 2026. The share of public money under each definition is on the evaluations page.
Against the Haut-commissariat's perimeters of aid to companies:
- not placed: the report lists no measure of this line
The literature
The studies that touch this line
Riou França L et al. (2013). A cohort study of therapeutic prescriptions after the end of phytotherapy drug reimbursement by French Social Security. Pharmacoepidemiology and Drug Safety.
- Design, as recorded: exposed cohort vs historical control cohort
- Goal measured: an outcome that is not one of the line's goals; its reading has no colour and is not counted
- Impact: adverse « patients exposed to de-reimbursement were more likely to switch to psychotropic drugs (OR = 1.46) »
- Leakage: leakage found « patients exposed to de-reimbursement were more likely to switch to psychotropic drugs (OR = 1.46) »
- Permanence: not informed
- another outcome, not counted
- a study of a cut
Marion Tano et al. (2023). What About Offering a Financial Incentive Directly to Clinical Units to Encourage the Use of Biosimilars? Results of a Two-Year National Experiment in France. Applied Health Economics and Health Policy.
- Design, as recorded: difference-in-differences with propensity score matching
- Goal measured: Efficiency and medically guided control of spending on medicines
- Impact: effect « The French experimental incentive appeared to be more effective at increasing biosimilar use. »
- Leakage: not informed
- Permanence: not informed
Marion Tano et al. (2024). Comparison of Two Financial Incentives to Encourage the Use of Adalimumab Biosimilars: Results of a French Experiment Close to Clinicians. PharmacoEconomics - Open.
- Design, as recorded: WEAK: retrospective comparison of experimental vs general-case hospitals (non-randomised)
- Goal measured: Efficiency and medically guided control of spending on medicines
- Impact: effect « General case hospitals had a significantly lower mean biosimilar uptake (16.7% vs 23.2%, p = 0.029) »
- Leakage: not informed
- Permanence: not informed
S. Lecerf et al. (2026). Long-term effect of discontinuing anticholinesterase treatment on cognitive decline and mortality in Alzheimer's disease in France: a quasi-experiment and target trial emulation study. The Lancet Regional Health - Europe.
- Design, as recorded: quasi-experiment / target trial emulation: discontinuers after delisting vs continuers
- Goal measured: an outcome that is not one of the line's goals; its reading has no colour and is not counted
- Impact: mixed « declined faster cognitively than those who continued »
- Leakage: not informed
- Permanence: not informed
- another outcome, not counted
- a study of a cut
Vincent Attia et al. (2024). Biosimilar Prescribing Incentives: Results of a French Pilot of Gainsharing Between Hospitals and the National Health Insurance. Economie et Statistique / Economics and Statistics n° 542, pp. 147-168 (HAL hal-05196106).
- Design, as recorded: Difference in differences against comparable facilities outside the pilot, with a doubly robust estimator (propensity score and outcome regression); placebo pre-trend tests not significant; volunteer hospitals, a local effect the authors say cannot be extrapolated; the etanercept effect significant at 7%
- Goal measured: Efficiency and medically guided control of spending on medicines
- Impact: effect « the pilot led to an increase in biosimilar use for insulin glargine (+6.0 percentage points) and etanercept (+10.8 ppt) »
- Leakage: not informed
- Permanence: not informed
Sylvain Pichetti et al. (2011). Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on prescription rates: a time-series analysis for France 1998-2010. Health Policy 102(2-3), pp. 159-169.
- Design, as recorded: Interrupted time series (linear segmented regression of prescription rates) on a physician panel, 1998-2010, with no concurrent control series
- Goal measured: an outcome that is not one of the line's goals; its reading has no colour and is not counted
- Impact: effect « the prescription rate for mucolytics declined significantly »
- Leakage: leakage found « we recorded an increase in the prescription rates for antitussives and bronchodilators »
- Permanence: not informed
- another outcome, not counted
- a study of a cut
Each study is coded by this site from the phrase quoted beside each verdict: impact on the goal it measures, leakage to people the law does not target, and permanence where the aim is a lasting change. The rows are in criteria.csv and studies.csv.
Searches
When the literature was searched
- 2026-10-04: every line, for causal evaluations of its measures and rules. Searched: the HAL, Crossref, OpenAlex, PubMed and IDEAS/RePEc catalogues of research and publishers' pages, line by line, and a general web search engine until its allowance ran out; some research departments' sites refused automated access, so a study they publish may have been missed (data/literature/gaps). Found: literature/studies.csv.
- 2026-10-19: causal evaluations of the reimbursement of medicines and medical devices published since the search of 4 October 2026, and older ones the search notes lack: generic substitution rules, biosimilar incentives, delisting, price regulation, co-payments on medicines, the reform that made some glasses and hearing aids free, early access and the hospital add-on list. Searched: the PubMed API (24 queries), the OpenAlex API (29 queries, then refused for the day), the HAL API (17 queries), the Crossref API (12 queries), the Irdes site (its lists of Questions d'économie de la santé and working papers), the Insee site; HAL's file server answered with a bot check, and the Drees and Cour des comptes sites' searches returned no usable results. Found: two studies coded as rows 379 and 380 (a biosimilar gain-sharing pilot, Economie et Statistique 2024; the 2006 delisting of mucolytics, Health Policy 2011); not coded: an Irdes before-and-after study of the same delisting (2007), studies of co-payments on declared behaviour, microsimulations, structural models, multi-country and descriptive studies; nothing causal on generic substitution rules, price regulation, the free glasses and hearing aids or the homeopathy delisting.